Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Macaya, Douoguih"'
Autor:
Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThis phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consec
Externí odkaz:
https://doaj.org/article/65e3268d9a954502879e597a8bb39643
Autor:
Marie Alexandre, Mélanie Prague, Chelsea McLean, Viki Bockstal, Macaya Douoguih, Rodolphe Thiébaut, for the EBOVAC 1 and EBOVAC 2 Consortia
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody conce
Externí odkaz:
https://doaj.org/article/b4e5f69ddd924ba2b6aadab80bc202e9
Autor:
Julie A. Ake, Kristopher Paolino, Jack N. Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Michael A. Eller, Margaret C. Costanzo, Dominic Paquin-Proulx, Merlin L. Robb, Chi L. Tran, Lalaine Anova, Linda L. Jagodzinski, Lucy A. Ward, Nicole Kilgore, Janice Rusnak, Callie Bounds, Christopher S. Badorrek, Jay W. Hooper, Steven A. Kwilas, Ine Ilsbroux, Dickson Nkafu Anumendem, Auguste Gaddah, Georgi Shukarev, Viki Bockstal, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Publikováno v:
Vaccines, Vol 12, Iss 5, p 497 (2024)
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adul
Externí odkaz:
https://doaj.org/article/d508ae26d5664c20827179054ade0b7e
Autor:
Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, Beatrice Kamala, Daniela Manno, Deborah Watson-Jones, Auguste Gaddah, Babajide Keshinro, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Publikováno v:
Vaccines, Vol 12, Iss 2, p 210 (2024)
In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, o
Externí odkaz:
https://doaj.org/article/be0eda68b7b14bcebefc7094a6d47a12
Autor:
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Macaya Douoguih, Cynthia Robinson, Laura Solforosi, Dominika Czapska-Casey, Liesbeth Dekking, Yvonne Wollmann, Ariane Volkmann, Maria Grazia Pau, Benoit Callendret, Jerry Sadoff, Hanneke Schuitemaker, Roland Zahn, Kerstin Luhn, Jenny Hendriks, Ramon Roozendaal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionIn the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals, in a statistical approach called immuno
Externí odkaz:
https://doaj.org/article/aad84e5ba566494dbfbc8dd3349ac928
Autor:
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for the two-dose Ebola vaccine
Externí odkaz:
https://doaj.org/article/62001c2a26ba43fdbeac3ea1080907ee
Autor:
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Seydou Doumbia, Sodiomon B. Sirima, Alimamy Serry-Bangura, Abdoul Habib Beavogui, Auguste Gaddah, Michael Katwere, Jenny Hendriks, Babajide Keshinro, Serge Eholie, Hannah Kibuuka, Stephen B. Kennedy, Omu Anzala, Mohamed Samai, Eric D'Ortenzio, Bailah Leigh, Samba Sow, Rodolphe Thiébaut, Brian Greenwood, Deborah Watson-Jones, Macaya Douoguih, Kerstin Luhn, Cynthia Robinson
Publikováno v:
EBioMedicine, Vol 91, Iss , Pp 104562- (2023)
Summary: Background: This analysis evaluated the immune response to the two-dose, heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen, administered 56-days apart, from multiple African sites based on results from one analytic laboratory.
Externí odkaz:
https://doaj.org/article/98953bd35c35430fa334e7636ba9a326
Autor:
Daniela Manno, Philip Ayieko, David Ishola, Muhammed O. Afolabi, Baimba Rogers, Frank Baiden, Alimamy Serry-Bangura, Osman M. Bah, Brian Köhn, Ibrahim Swaray, Kwabena Owusu-Kyei, Godfrey T. Otieno, Dickens Kowuor, Daniel Tindanbil, Elizabeth Smout, Cynthia Robinson, Babajide Keshinro, Julie Foster, Katherine Gallagher, Brett Lowe, Macaya Douoguih, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 3, Pp 734-738 (2022)
We explored the association of Ebola virus antibody seropositivity and concentration with potential risk factors for infection. Among 1,282 adults and children from a community affected by the 2014–2016 Ebola outbreak in Sierra Leone, 8% were serop
Externí odkaz:
https://doaj.org/article/2254071766d6435e89e08cf0d179f013
Autor:
Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV and MVA-BN-Filo. Study 1 evaluated the
Externí odkaz:
https://doaj.org/article/7c2795f7e19c4f3e9ae22a1cfba61a16
Autor:
Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to re
Externí odkaz:
https://doaj.org/article/e15b3df185804c61b1c2049c272a25ed